Cargando…

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)

Detalles Bibliográficos
Autores principales:	Hamadani, M., Coleman, M., Boccia, R., Duras, J., Hutchings, M., Zinzani, P. L., Cordoba, R., Oreiro, M. B., Williams, V., Stouffs, M., Langmuir, P., Sancho, J.-M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431125/ http://dx.doi.org/10.1097/01.HS9.0000847284.03476.7b

Ejemplares similares

P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112): PRELIMINARY SAFETY RESULTS
por: Sancho, J.-M., et al.
Publicado: (2022)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
por: Trněný, Marek, et al.
Publicado: (2023)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study
por: Fukuhara, Noriko, et al.
Publicado: (2022)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma
por: Ueda, Yayoi, et al.
Publicado: (2022)

The Citadel of the Senses
por: Wilson, M. G.
Publicado: (1986)

The Citadel of the Senses
por: Brown, Robert K.
Publicado: (1986)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

Prolonged SARS‐CoV‐2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report
por: Kambe, Ryosuke, et al.
Publicado: (2023)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Bendamustine/obinutuzumab: COVID-19 disease, pancytopenia and hypogammaglobulinaemia: case report
Publicado: (2021)

Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab
por: Franceschini, Erica, et al.
Publicado: (2023)

The citadel of freedom : a brief study of the Constitution and its builders, and of the movement to destroy it
por: Leigh, Randolph, 1891-
Publicado: (1924)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
por: Stilgenbauer, Stephan, et al.
Publicado: (2018)

Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Breaking out of the citadel: social theory and psychiatry
por: Poole, Rob, et al.
Publicado: (2023)

Bendamustine/ciclesonide/obinutuzumab: Diarrhoea following off-label use and prolonged viral shedding: case report
Publicado: (2021)

Reduced bendamustine for elderly patients with follicular lymphoma
por: Masamoto, Yosuke, et al.
Publicado: (2021)

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
por: Cheson, Bruce D., et al.
Publicado: (2016)

Bendamustine/obinutuzumab/remdesivir: Absence of CD19-B lymphocytes, decrease in CD4-T lymphocytes and lack of efficacy: case report
Publicado: (2021)

A tale of two citadels: memoirs of a surgeon and his times
por: Williams, David Innes
Publicado: (1995)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Results and Complications of 1104 Surgeries for Velopharyngeal Insufficiency
por: Hirschberg, Jenő
Publicado: (2012)

1104. Antibiotic Prophylaxis for the Endoscopic Endonasal Approach
por: DeKerlegand, Alaina, et al.
Publicado: (2019)

A case of neurolymphomatosis caused by follicular lymphoma successfully treated with bendamustine
por: Umeda, Masayuki, et al.
Publicado: (2015)

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model
por: Decaup, E, et al.
Publicado: (2013)

Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy
por: Jamois, Candice, et al.
Publicado: (2019)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study
por: Yamasaki, Satoshi, et al.
Publicado: (2021)

Criminals in the Citadel and Deceit all along the Watchtower: Irresponsibility, Fraud, and Complicity in the Search for Scientific Truth
por: Tharyan, Prathap
Publicado: (2012)

Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab—Challenging Recognition and Treatment
por: Łyżwa, E., et al.
Publicado: (2023)

Disseminated Enteroviral Infection Associated with Obinutuzumab
por: Dendle, Claire, et al.
Publicado: (2015)

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma
por: Davies, Andrew, et al.
Publicado: (2020)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Network for Development of Electroporation-Based Technologies and Treatments: COST TD1104
por: Miklavčič, Damijan
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bo0nmq9csjbuv61721houa067t